BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18089333)

  • 1. Cyclosporine monitoring in peripheral blood mononuclear cells: feasibility and interest. A prospective study on 20 renal transplant recipients.
    Lepage JM; Lelong-Boulouard V; Lecouf A; Debruyne D; Hurault de Ligny B; Coquerel A
    Transplant Proc; 2007 Dec; 39(10):3109-10. PubMed ID: 18089333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients.
    Falck P; Asberg A; Guldseth H; Bremer S; Akhlaghi F; Reubsaet JL; Pfeffer P; Hartmann A; Midtvedt K
    Transplantation; 2008 Jan; 85(2):179-84. PubMed ID: 18212621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single daily dose administration of cyclosporine in renal transplant recipients.
    Halim MA; Said T; Al-Otaibi T; Eleawa S; Al-Maged H; Gawish AE; Nair P; Al-Muzairai I; Nampoory MR; Al-Mousawi M
    Transplant Proc; 2007 May; 39(4):1225-7. PubMed ID: 17524939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
    Bunnag S; Vareesangthip K; Ong-ajyooth L
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies.
    Sommerer C; Konstandin M; Dengler T; Schmidt J; Meuer S; Zeier M; Giese T
    Transplantation; 2006 Nov; 82(10):1280-5. PubMed ID: 17130775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring.
    Sharma A; Shekhar C; Heer M; Minz M
    Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine monitoring in stable, long-term, pediatric kidney transplant recipients: the value of C2 determination.
    Ferraresso M; Ghio L; Tirelli S; Pedotti P; Taioli E; Edefonti A; Berardinelli L
    Transplant Proc; 2004 Apr; 36(3):685-6. PubMed ID: 15110630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
    Carstens J
    Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P; Ortiz AM; Jara A; Vilches S
    Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine renal dysfunction.
    Vítko S; Viklický O
    Transplant Proc; 2004 Mar; 36(2 Suppl):243S-247S. PubMed ID: 15041346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of postdose cyclosporine monitoring in living renal transplant recipients.
    Thomas R; Minz M; Singh B; Heer M; Kashyap R
    Transplant Proc; 2004 Sep; 36(7):2104. PubMed ID: 15518761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients?
    Marin JG; Levine M; Ensom MH
    Ther Drug Monit; 2006 Oct; 28(5):637-42. PubMed ID: 17038878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
    Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
    Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
    Calvo-Turrubiartes M; Romano-Moreno S; García-Hernández M; Chevaile-Ramos JA; Layseca-Espinosa E; González-Amaro R; Portales-Pérez D
    Transpl Immunol; 2009 May; 21(1):43-9. PubMed ID: 19233271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
    Davies RA; Veinot JP; Williams K; Haddad H; Baker A; Donaldson J; Pugliese C; Struthers C; Masters RG; Hendry PJ; Mesana T
    Transplant Proc; 2007 Dec; 39(10):3334-9. PubMed ID: 18089382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients.
    Hendriks MP; Blijlevens NM; Schattenberg AV; Burger DM; Donnelly JP
    Bone Marrow Transplant; 2006 Oct; 38(7):521-5. PubMed ID: 16981000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal induced IL-2 mRNA monitoring in renal transplant patients immunosuppressed with cyclosporine and in unmodified canine renal transplant rejection.
    Zucker C; Zucker K; Asthana D; Carreno M; Viciana AL; Ruiz P; Esquenazi V; Nery J; Burke G; Miller J
    Hum Immunol; 1996 Jan; 45(1):1-12. PubMed ID: 8655354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidemia can reduce the immunosuppressive effects of cyclosporine.
    Pozzetto U; Citterio F; Fioravanti G; Navarra P; Boccalini F; Castagneto M
    Transpl Immunol; 2008 Feb; 18(4):349-51. PubMed ID: 18158122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.